Author(s):
Mansi Barot, Anuradha P. Prajapati, Neha Vadgama, Sachin B. Narkhede, Shailesh Luhar
Email(s):
anuradha@ssgsalvav.in
DOI:
10.52711/0974-360X.2025.00324 
Address:
Mansi Barot, Anuradha P. Prajapati*, Neha Vadgama, Sachin B. Narkhede, Shailesh Luhar
Department of Pharmaceutics, Smt. B.N.B. Swaminarayan Pharmacy College, Salvav, Vapi, Gujarat, India, 396191.
*Corresponding Author
Published In:
Volume - 18,
Issue - 5,
Year - 2025
ABSTRACT:
Introduction: Atopic dermatitis is a prevalent chronic inflammatory skin disorder, characterized by pruritus and the formation of eczematous lesions, significantly impairing the quality of life. Crisaborole, a non-steroidal phosphodiesterase-4 inhibitor, has shown promise in the treatment of Atopic Dermatitis due to its anti-inflammatory properties. However, the development of an efficient topical delivery system for Crisaborole remains a challenge, necessitating innovative approaches to enhance its skin permeability and therapeutic efficacy. Objective: This study aimed to develop and optimize a proniosomal gel formulation of Crisaborole, utilizing the coacervation phase separation technique in conjunction with a 32 full factorial design, to achieve enhanced drug encapsulation and sustained release for effective management of Atopic Dermatitis. Methodology: Proniosomes, as colloidal carriers, consist of non-ionic surfactants, soya lecithin, and cholesterol, which upon hydration, self-assemble into niosomes. These systems are known for their ability to enhance drug stability, bioavailability, and permeation. The coacervation phase separation method was employed to encapsulate Crisaborole within proniosomal vesicles, aiming to improve its topical delivery. The 32 full factorial design was utilized to systematically assess the effects of two independent variables on-ionic surfactant (X1) and cholesterol (X2) on critical parameters, including vesicle size and entrapment efficiency. Results: Optimized formulations were identified based on factorial analysis, with the most promising batch exhibiting a vesicle size of 175 nm and an entrapment efficiency of 87.57±0.020%. The proniosomal gel formulation was comprehensively characterized for parameters such as vesicle size, morphology, viscosity, spreadability, extrudability, drug release, and stability. In vitro release studies indicated a sustained release profile, suggesting prolonged topical efficacy. Conclusion: The optimized Crisaborole proniosomal gel demonstrated favourable physicochemical properties, including small vesicle size and high entrapment efficiency, making it a suitable candidate for the topical treatment of Atopic Dermatitis. The sustained drug release from the proniosomal system indicates its potential to enhance therapeutic outcomes through prolonged skin residence time and improved drug penetration.
Cite this article:
Mansi Barot, Anuradha P. Prajapati, Neha Vadgama, Sachin B. Narkhede, Shailesh Luhar. Formulation Development and Evaluation of Proniosomal Gel containing Crisaborole. Research Journal of Pharmacy and Technology. 2025;18(5):2261-8. doi: 10.52711/0974-360X.2025.00324
Cite(Electronic):
Mansi Barot, Anuradha P. Prajapati, Neha Vadgama, Sachin B. Narkhede, Shailesh Luhar. Formulation Development and Evaluation of Proniosomal Gel containing Crisaborole. Research Journal of Pharmacy and Technology. 2025;18(5):2261-8. doi: 10.52711/0974-360X.2025.00324 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-5-47
REFERENCES:
1. Nasr M. In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration. Sci Asia. 2010; 36:305-311.
2. Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm. 2005; 59(3): 485-490. doi: 10.1016/j.ejpb.2004.09.009
3. Chandra A, Sharma PK. Proniosome-based drug delivery system of piroxicam. Afr J Pharm Pharmacol. 2008; 2(9): 184-190.
4. Gupta A, Prajapati SK, Balamurugan M, Singh M, Bhatia D. Design and development of a proniosomal transdermal drug delivery system for captopril. Trop J Pharm Res. 2007; 6: 687-693.
5. Jhade D. Proniosomal gel as a carrier for improved transdermal delivery of griseofulvin: Preparation and in-vitro characterization. Pharmainfo.net. 2009; 15:24.
6. Kakar R, Singh R, Kaur I, Singh G. Proniosomes: An emerging vesicular system in drug delivery and cosmetics. Sch Res Libr. 2010;2(4):227-239.
7. Keservani RK, Sharma AK, Ayaz M, Kesharwani R. Novel drug delivery system for the vesicular delivery of drugs by niosomes. Int J Res Control Release. 2011;1(1):1-8.
8. Khatoon M, Mishra SK, Verma A, Vyas N. Proniosomes derived niosomes: Recent advancements in drug delivery and targeting. Drug Deliv. 2017; 24(2): 56-69. doi:10.1080/10717544.2017.1377367
9. Kondawar MS, Kamble KG, Malusare MK, Waghmare JJ, Shah ND. Proniosome based drug delivery system for clotrimazole. Res J Pharm Technol. 2011; 4(8): 1284-1287.
10. Kumar K, Rai AK. Development and evaluation of proniosome encapsulated curcumin for transdermal administration. Trop J Pharm Res. 2011; 1(6): 697-703.
11. Lakshmi Radhika K, Dinesh Kumar B, Krishnakumar K. Proniosomal gel: A novel approach for drug delivery – A review. Indo Am J Pharm Sci. 2017; 7(3): 7854-7860.
12. Mishra A, Yadav P, Tiwari S, Mishra S. Proniosomal gel as a carrier for improved transdermal drug delivery. Asian J Pharm Life Sci. 2011; 1(4): Oct-Dec.
13. Nasr M. In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration. AAPS PharmSciTech. 2010; 11(1): 85-89. doi:10.1208/s12249-009-9376-9
14. Prajapati AP, Narkhede SB, Kanzaria JH. A review on in situ gel therapy for epilepsy via nasal route. J Pharmacogn Phytochem. 2019; 8(3): 4809-4814.
15. Radha GV, Rani TS, Sarvani B. A review on proniosomal drug delivery system for targeted drug action. J Basic Clin Pharm. 2013;4(2):42. doi:10.4103/0976-0105.119667
16. Rekha K, Kuldeep V, Aatish V, Girish KY, Sheo DM. Proniosomes: A key to improved drug delivery. J Drug Deliv Ther. 2014;1:56-65.
17. Sundaresan P, Sravanthi C, Gowtham T. Evaluation of aceclofenac niosomes prepared by various techniques. Int J Pharm Sci Rev Res. 2012; 16(1): 75-78.
18. Sakthivel M, Kannan K, Manavalan R, Senthamarai R. Formulation and in vivo evaluation of niosomes containing oxcarbazepine. J Pharm Sci Res. 2013; 5(1): 8.
19. Solankhi A, Parikh J, Parikh R. Preparation, characterization, optimization, and stability studies of aceclofenac proniosomes. Iran J Pharm Res. 2008; 7(4): 237-246.
20. Srikanth M, Nappinnai VRM, Gupta V. Proniosomes: A novel drug carrier system. Res J Pharm Technol. 2010; 3(3): 709-711.
21. Sudhamani T, Sarvanan G, Arul Kumar S. Formulation and evaluation of ibuprofen-loaded maltodextrin-based proniosome. Int J Biopharm. 2010; 1(2): 75-81.
22. Tamer M, Shahein SA, Naggib WM, Ahmed AR. Proniosomal oral tablets for controlled delivery and enhanced pharmacokinetic properties of acemetacin. AAPS PharmSciTech. 2015; 16(2): 375-383. doi:10.1208/s12249-014-0223-9
23. Yadav N, Saroha K, Nanda S. Proniosome gel: Potential carrier system in topical/transdermal delivery for drugs and cosmetics/cosmeceuticals. Pharmainfo.net. 2008; 8(2).